The burgeoning landscape of therapeutic interventions for weight disorders has witnessed considerable attention focused on GLP-3 receptor agonists and, more recently, the dual GIP and GLP-3 co-agonist retatrutide. https://iwanqkdd269951.blogmazing.com/37951280/glp-3-retatrutide-a-comparative-analysis